Nexvet's $40M IPO Pricing Adds To Rough Day For Biotechs

Law360, New York (February 5, 2015, 3:19 PM EST) -- Animal medicine developer Nexvet Biopharma PLC priced an initial public offering below range Thursday, raising about $40 million, and watched shares slide further in debut trading, the latest in a flurry of life science IPOs on a rocky day that saw another company postpone plans.

Ireland-based Nexvet priced 4 million shares at $10 on the Nasdaq, down from an earlier range of $13 to $16. The shares subsequently dipped $1.25, or 12.5 percent, to $8.75 in debut trading Thursday afternoon under symbol NVET.

The choppy debut came the same day that France-based Advanced Accelerator Applications, a radiopharmaceutical diagnostics company developing its...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS